Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06848231
PHASE2

A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy

Sponsor: Dasher Neuroscience Inc.

View on ClinicalTrials.gov

Summary

This is a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.

Official title: A Double-Blind, Placebo-Controlled, Multi-Center, Phase II, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of YA-101 in Subjects With Multiple System Atrophy

Key Details

Gender

All

Age Range

30 Years - Any

Study Type

INTERVENTIONAL

Enrollment

75

Start Date

2025-03-03

Completion Date

2026-12-31

Last Updated

2025-09-10

Healthy Volunteers

No

Interventions

DRUG

YA-101

Drug: YA-101 • YA-101 taken BID

DRUG

Placebo

Placebo taken BID

Locations (9)

UCLA Health

Los Angeles, California, United States

Brigham and Women's Hospital

Boston, Massachusetts, United States

Mayo Clinic

Rochester, Minnesota, United States

Columbia University Irving medical center

New York, New York, United States

Vanderbilt University Medical Center

Nashville, Tennessee, United States

Baylor College of Medicine

Houston, Texas, United States

Juntendo University Hospital

Tokyo, Japan

National Taiwan University Hospital

Taipei, Taiwan

National Taiwan University Hospital Cancer Center

Taipei, Taiwan